




RealRate

PHARMACEUTICAL 2022

Altimmune Inc.
Rank 269 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Altimune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Altimune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is -147%, being 130% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	204,126
Cost of Goods Sold	0
Intangible Assets	12,419
Liabilities, Current	18,276
Liabilities, Non-Current	0
Other Assets	872
Other Compr. Net Income	4.4
Other Expenses	11,370
Other Liabilities	1,454
Other Net Income	-177
Property and Equipment	1,448
Research and Development	74,541
Revenues	4,410
Selling, General and Administrative Expense	15,413

Output Variable	Value in 1000 USD
Assets	218,865
Liabilities	19,730
Expenses	101,324
Stockholders Equity	199,135
Net Income	-97,091
Comprehensive Net Income	-97,089
Economic Capital Ratio	-147%